133 related articles for article (PubMed ID: 9279289)
1. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
van Barlingen HH; van Beek A; Erkelens DW; de Bruin TW
J Intern Med; 1997 Aug; 242(2):125-9. PubMed ID: 9279289
[TBL] [Abstract][Full Text] [Related]
2. Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans.
Mikhailidis DP; Jagroop IA
J Intern Med; 1998 Aug; 244(2):184. PubMed ID: 10095808
[No Abstract] [Full Text] [Related]
3. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
Wilde MI; Markham A
Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
[TBL] [Abstract][Full Text] [Related]
4. [Thrombocytopenia due to heparin therapy. Use of danaparoid (Orgaran), 13 monocentric cases under authorization of temporary prescription (ATU)].
Gindre L; de Maistre E; Perrin A; Lecompte T; Hoffman MA
Therapie; 1997; 52(6):591-7. PubMed ID: 9734113
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study.
de Pont AC; Hofstra JJ; Pik DR; Meijers JC; Schultz MJ
Crit Care; 2007; 11(5):R102. PubMed ID: 17854496
[TBL] [Abstract][Full Text] [Related]
6. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation.
Zmuda K; Neofotistos D; Ts'ao CH
Am J Clin Pathol; 2000 May; 113(5):725-31. PubMed ID: 10800406
[TBL] [Abstract][Full Text] [Related]
7. Danaparoid in the prevention of thromboembolic complications.
Skoutakis VA
Ann Pharmacother; 1997; 31(7-8):876-87. PubMed ID: 9220051
[TBL] [Abstract][Full Text] [Related]
8. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
Gitlin SD; Deeb GM; Yann C; Schmaier AH
J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
[TBL] [Abstract][Full Text] [Related]
9. Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.
Zammit A; Dawes J
Thromb Haemost; 1994 Jun; 71(6):759-67. PubMed ID: 7526481
[TBL] [Abstract][Full Text] [Related]
10. [Heparin-associated platelet aggregation syndrome with skin necrosis during hemodialysis].
Bredlich RO; Stracke S; Gall H; Proebstle TM
Dtsch Med Wochenschr; 1997 Mar; 122(11):328-32. PubMed ID: 9102281
[TBL] [Abstract][Full Text] [Related]
11. [Danaparoid sodium for dialysis in heparin-associated thrombocytopenia].
Ben Ami R; Rachmimov R; Berliner S
Harefuah; 1999 Mar; 136(5):361-4, 419. PubMed ID: 10914239
[TBL] [Abstract][Full Text] [Related]
12. Clinical cross-reactivity between danaparoid and heparin antibodies successfully managed with bivalirudin.
Shapiro M; Cohen J; Inbal A; Singer P
Isr Med Assoc J; 2009 Mar; 11(3):188-90. PubMed ID: 19544713
[No Abstract] [Full Text] [Related]
13. A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.
Takahashi H; Ebihara S; Okazaki T; Asada M; Sasaki H; Yamaya M
Br J Pharmacol; 2005 Oct; 146(3):333-43. PubMed ID: 16041398
[TBL] [Abstract][Full Text] [Related]
14. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat.
Miyake Y; Yokota K; Fujishima Y; Sukamoto T
Blood Coagul Fibrinolysis; 2001 Jul; 12(5):349-57. PubMed ID: 11505077
[TBL] [Abstract][Full Text] [Related]
15. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls.
Burgess JK; Chong BH
Eur J Haematol; 1997 Apr; 58(4):279-85. PubMed ID: 9186540
[TBL] [Abstract][Full Text] [Related]
16. Standard heparin, low molecular weight heparin, low molecular weight heparinoid, and recombinant hirudin differ in their ability to inhibit transduction by recombinant adeno-associated virus type 2 vectors.
Hacker UT; Gerner FM; Büning H; Hutter M; Reichenspurner H; Stangl M; Hallek M
Gene Ther; 2001 Jun; 8(12):966-8. PubMed ID: 11426338
[TBL] [Abstract][Full Text] [Related]
17. Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate.
Ofosu FA; Modi GJ; Blajchman MA; Buchanan MR; Johnson EA
Biochem J; 1987 Dec; 248(3):889-96. PubMed ID: 2963622
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients.
Severin T; Zieger B; Sutor AH
Semin Thromb Hemost; 2002 Oct; 28(5):447-54. PubMed ID: 12420240
[TBL] [Abstract][Full Text] [Related]
19. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.
de Valk HW; Banga JD; Wester JW; Brouwer CB; van Hessen MW; Meuwissen OJ; Hart HC; Sixma JJ; Nieuwenhuis HK
Ann Intern Med; 1995 Jul; 123(1):1-9. PubMed ID: 7539233
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of danaparoid sodium, dalteparin sodium and heparin determined by inhibitory effect on the activated coagulation factor X activity after single intravenous administration in rabbits.
Ishida M; Nakada Y; Horiuchi M; Sakamoto F
Arzneimittelforschung; 1998 Aug; 48(8):818-21. PubMed ID: 9748709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
